[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100609026":3},{"organization":4,"armGroups":7,"interventions":29,"overallOfficials":47,"centralContacts":53,"locations":62,"responsibleParty":79,"collaborators":82,"id":86,"slug":87,"hasResults":88,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":94,"sex":95,"minAge":96,"maxAge":97,"enrollmentInfo":98,"targetDuration":34,"studyType":101,"phases":102,"briefSummary":104,"conditions":105,"keywords":108,"overallStatus":65,"whyStopped":34,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":120},{"fullName":5,"class":6},"Touro University, California","OTHER",[8,15,20,25],{"label":9,"type":10,"description":11,"interventionNames":12},"High fructose meals, oral 13C fructose","EXPERIMENTAL","Liquid meals will be fed, containing 55% total carbohydrate (16% fructose), 30% fat, 15% protein, and a tracer amount of 13C fructose.",[13,14],"Other: High fructose meal","Other: 13C labeled fructose, oral",{"label":16,"type":10,"description":17,"interventionNames":18},"High Fructose Meals, IV 13C Fructose","Liquid meals will be fed, containing 55% total carbohydrate (16% fructose), 30% fat, 15% protein. A tracer amount of 13C fructose will be administered intravenously.",[13,19],"Other: 13C labeled fructose, intravenous",{"label":21,"type":10,"description":22,"interventionNames":23},"Low fructose meals, oral fructose tracer","Liquid meals will be fed, containing 55% total carbohydrate (6% fructose), 30% fat, 15% protein, and a tracer amount of 13C fructose.",[24,14],"Other: Low fructose meal",{"label":26,"type":10,"description":27,"interventionNames":28},"Low fructose meals, IV 13C fructose tracer","Liquid meals will be fed, containing 55% total carbohydrate (6% fructose), 30% fat, 15% protein. A tracer amount of 13C fructose will be administered intravenously.",[24,19],[30,35,39,43],{"type":6,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"High fructose meal","Liquid meals containing 55% total carbohydrate (16% fructose), 30% fat, 15% protein.",[16,9],null,{"type":6,"name":36,"description":37,"armGroupLabels":38,"otherNames":34},"Low fructose meal","55% total carbohydrate (6% fructose), 30% fat, 15% protein.",[26,21],{"type":6,"name":40,"description":41,"armGroupLabels":42,"otherNames":34},"13C labeled fructose, oral","Tracer amount of 13C labeled fructose administered orally in the meals.",[9,21],{"type":6,"name":44,"description":45,"armGroupLabels":46,"otherNames":34},"13C labeled fructose, intravenous","Tracer amount of 13C fructose administered intravenously",[16,26],[48,51],{"name":49,"affiliation":5,"role":50},"Jean-Marc Schwarz, PhD","PRINCIPAL_INVESTIGATOR",{"name":52,"affiliation":5,"role":50},"Grace M Jones, PhD",[54,59],{"name":55,"role":56,"phone":57,"phoneExt":34,"email":58},"Sally Chiu, PhD","CONTACT","707-638-5404","schiu2@touro.edu",{"name":60,"role":56,"phone":34,"phoneExt":34,"email":61},"Lisa Johnson, RN","ljohnson19@touro.edu",[63],{"facility":64,"status":65,"city":66,"state":67,"zip":68,"country":69,"countryCode":70,"cosmosGeoPoint":71,"geoPoint":76,"contacts":77},"Touro University California","RECRUITING","Vallejo","California","95492","United States","US",{"type":72,"coordinates":73},"Point",[74,75],-122.25664,38.10409,{"lat":75,"lon":74},[78],{"name":55,"role":56,"phone":34,"phoneExt":34,"email":58},{"type":50,"investigatorFullName":80,"investigatorTitle":81,"investigatorAffiliation":5,"oldNameTitle":34,"oldOrganization":34},"Jean-marc Schwarz","Professor",[83],{"name":84,"class":85},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","NIH","100609026","fructose-intestinal-gluconeogenesis-100609026",false,"NCT07209202","Fructose Intestinal Gluconeogenesis","Fructose Metabolism Effects on the Liver: Unraveling the Role of Defective Intestinal GNG in Individuals With Obesity","FIG","Inclusion Criteria:\n\n* BMI 30 to 38 kg\u002Fm2 (obese group) or BMI 19 to 25 kg\u002Fm2 (lean group)\n\nExclusion Criteria:\n\n* Pregnancy or lactation within the past six months;\n* Type 1 or 2 diabetes mellitus (including fasting glucose ≥126 mg\u002FdL, HgbA1c ≥6.5%);\n* History of liver disease or AST and ALT 2x above the upper limit of normal;\n* Fasting triglyceride \\> 300 mg\u002Fdl; total cholesterol levels above the 95th percentile for age and sex;\n* Hemoglobin (Hgb) \\\u003C12.5g\u002Fd or hematocrit\\\u003C3x Hgb value;\n* Report of HIV or hepatitis B or C infection;\n* History of cancer, other than basal cell or squamous cell carcinoma or kidney disease stage 3 or higher or patients currently on dialysis;\n* Use of any anti-diabetic medications or hypolipidemic agents in the past six months;\n* History of surgical procedure for obesity;\n* Change in body weight \\>5% in the past six months (by self-report);\n* History of other conditions known to affect insulin sensitivity and lipid metabolism (e.g., polycystic ovary syndrome), history of galactosemia, hereditary fructose intolerance, or who test positive for fructose malabsorption at screening;\n* Known intolerance to acetaminophen.",true,"ALL","20 Years","55 Years",{"count":99,"type":100},40,"ESTIMATED","INTERVENTIONAL",[103],"NA","This study will test the hypothesis that within a defined range of fructose intake, the ability to convert fructose to glucose (via gluconeogenesis) in the small intestine plays a protective role for the liver, shielding it from the deleterious effects of fructose. We will investigate whether this protective effect of the intestine is impaired in individuals with obesity.",[106,107],"Healthy Participants","Obese But Otherwise Healthy Participants",[109,110],"Fructose","Sugar","2026-03-04",{"date":113,"type":114},"2026-03-06","ACTUAL",{"date":116,"type":114},"2026-03-02",{"date":118,"type":100},"2030-06",{"name":5,"class":6},1]